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Abstract
Background: Griseofulvin, an antifungal drug, has recently been shown to inhibit proliferation of various types of 
cancer cells and to inhibit tumor growth in athymic mice. Due to its low toxicity, griseofulvin has drawn considerable 
attention for its potential use in cancer chemotherapy. This work aims to understand how griseofulvin suppresses 
microtubule dynamics in living cells and sought to elucidate the antimitotic and antiproliferative action of the drug.
Methods: The effects of griseofulvin on the dynamics of individual microtubules in live MCF-7 cells were measured by 
confocal microscopy. Immunofluorescence microscopy, western blotting and flow cytometry were used to analyze the 
effects of griseofulvin on spindle microtubule organization, cell cycle progression and apoptosis. Further, interactions 
of purified tubulin with griseofulvin were studied in vitro by spectrophotometry and spectrofluorimetry. Docking 
analysis was performed using autodock4 and LigandFit module of Discovery Studio 2.1.
Results: Griseofulvin strongly suppressed the dynamic instability of individual microtubules in live MCF-7 cells by 
reducing the rate and extent of the growing and shortening phases. At or near half-maximal proliferation inhibitory 
concentration, griseofulvin dampened the dynamicity of microtubules in MCF-7 cells without significantly disrupting 
the microtubule network. Griseofulvin-induced mitotic arrest was associated with several mitotic abnormalities like 
misaligned chromosomes, multipolar spindles, misegregated chromosomes resulting in cells containing fragmented 
nuclei. These fragmented nuclei were found to contain increased concentration of p53. Using both computational and 
experimental approaches, we provided evidence suggesting that griseofulvin binds to tubulin in two different sites; 
one site overlaps with the paclitaxel binding site while the second site is located at the αβ intra-dimer interface. In 
combination studies, griseofulvin and vinblastine were found to exert synergistic effects against MCF-7 cell 
proliferation.
Conclusions: The study provided evidence suggesting that griseofulvin shares its binding site in tubulin with paclitaxel 
and kinetically suppresses microtubule dynamics in a similar manner. The results revealed the antimitotic mechanism 
of action of griseofulvin and provided evidence suggesting that griseofulvin alone and/or in combination with 
vinblastine may have promising role in breast cancer chemotherapy.
Background
Griseofulvin (GF), an orally active antifungal drug, has
been attracting considerable interest as a potential anti-
cancer agent owing to its low toxicity and efficiency in
inhibiting the proliferation of different types of cancer
cells [1-4]. GF in combination with nocodazole was
shown to potently inhibit tumor growth in athymic mice
[1]. It induces apoptosis in several cancer cell lines [5] and
it has also been proposed that GF can selectively kill the
cancer cells sparing the normal healthy cells [3].
GF is known to inhibit the growth of fungal, plant and
mammalian cells mainly by inducing abnormal mitosis
and blocking the cells at G2/M phase of cell cycle [1-3,6-
8]. Different organisms exhibit different degrees of sensi-
tivity to GF owing to its differential affinity to different
tubulins [6,9]. The concentration required to inhibit the
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growth of fungal cells is much lower than that required to
inhibit the mammalian cells due to its higher affinity for
fungal tubulin as compared to the mammalian tubulin
[6,10-12]. GF has been reported to interact with tubulin
[2,12-16] as well as microtubule associated proteins
(MAPs) [13,17].
Recently, GF has been shown to suppress the dynamic
instability of MAPs-free microtubules in vitro [2]. The
spindle microtubules of HeLa cells treated with moderate
concentrations of GF appeared to have nearly normal
organization [2,18], while higher GF concentration
caused depolymerization of the microtubules [2,16].
Based on the strong suppressive effects of GF on the
microtubule dynamics in vitro, it was proposed that GF
inhibits mitosis in HeLa cells by suppressing microtubule
dynamics [2].
Although several studies suggested that tubulin is the
primary target of GF [2,12,14-16], the binding site of GF
in tubulin is yet unknown. Based on the findings that GF
quenches tryptophan fluorescence of the colchicine-
tubulin complex [12] and that colchicine can depolymer-
ize GF-induced polymers of tubulin in the presence of
MAPs at 4°C [13], it was suggested that GF binds at a site
distinct than the colchicine binding site in tubulin [12].
In this study, we have identified two potential binding
sites for GF in mammalian tubulin and provided a mech-
anistic explanation of how GF stabilizes microtubule
dynamics. Further, the data suggested that GF inhibited
mitosis in MCF-7 cells by suppressing the dynamicity of
microtubules and that a population of the mitotically
blocked cells escaped mitosis with misegregated chromo-
somes and eventually underwent apoptotic cell death.
Methods
Materials
GF, paclitaxel, vinblastine, mouse monoclonal anti-α
tubulin IgG, rabbit monoclonal anti-γ tubulin IgG, alka-
line phosphatase conjugated anti-mouse IgG, FITC (fluo-
rescein isothiocyanate) conjugated anti-mouse IgG, fetal
bovine serum, bovine serum albumin and Hoechst 33258
were purchased from Sigma (St. Louis, MO, USA). Mouse
monoclonal anti-BubR1 antibody was purchased from
BD Pharmingen (San Diego, USA). Rabbit polyclonal
anti-Mad2 IgG was purchased from Bethyl laboratories
(Montgomery, USA). Mouse monoclonal anti-Hec 1 IgG
was purchased from Abcam (Cambridge, MA, USA).
Anti-Mouse IgG alexa 568 conjugate and lipofectamine-
2000 were purchased from Invitrogen (Carlsbad, CA,
USA). Mouse monoclonal anti-p53 IgG, mouse monoclo-
nal anti-p21 IgG, rabbit polyclonal anti-phosphohistone
IgG and Annexin V apoptosis detection kit were pur-
chased from Santa Cruz Biotechnology (CA, USA). All
other reagents were of analytical grade.
Effects of GF on MCF-7 cells and on the cell cycle 
progression
MCF-7 cells (1 × 105 cells/mL) were grown in 96-well tis-
sue culture plates at 37°C for 24 h [19]. Then the medium
was replaced with fresh medium containing vehicle (0.1%
DMSO) or different concentrations of GF and the cells
were grown for additional 48 h. Both attached and float-
ing cells were harvested with the help of trypsin-EDTA
solution and counted after staining with trypan blue [2].
MCF-7 cells were grown on glass coverslips in the
absence or presence of different concentrations of GF for
24 h and the mitotic index was calculated by staining the
chromosomes with Hoechst dye [19,20].
For determining the effect of GF on cell cycle progres-
sion, MCF-7 cells were grown for 48 h (one cell cycle)
without or with different concentrations of GF. Samples
were prepared as described recently [21]. DNA content of
the cells was quantified in a flow cytometer (FACS Aria
special order system, Becton Dickinson) and the cell cycle
distribution was analyzed using the Modfit LT program
[21].
Immunofluorescence Microscopy
MCF-7 cells (5 × 104 cells/mL) were grown on glass cov-
erslips in 24 well tissue culture plates for 24 h [19,20].
Then, the medium was replaced with fresh medium con-
taining vehicle (0.1% DMSO) or different concentrations
of GF (15, 30, 60 and 90 μM) and the incubation contin-
ued for further 24 or 48 h. The cells were then fixed with
3.7% formaldehyde at 37°C for 30 min and processed to
visualize α tubulin, γ tubulin, p53, p21, BubR1, Mad2,
Hec1 and phosphohistone [19,20].
Analysis of the polymeric mass of tubulin
MCF-7 cells were incubated without or with different
concentrations of GF (15, 30, 60 and 90 μM) for 48 h. The
e ff ect  of  G F on t he  am o un t  o f  polym e rized t u buli n in
MCF-7 cells was estimated by western blot analysis using
anti α-tubulin antibody as described earlier [19] and the
band intensities were estimated using Image J software.
The band intensities for polymeric and soluble tubulin in
the presence of different concentrations of GF were nor-
malized with that of the vehicle-treated MCF-7 cells. The
normalized band intensities were plotted against GF con-
centrations.
Transfection of EGFP-α tubulin and measurement of 
microtubule dynamics
The effects of GF on the dynamic instability of individual
microtubules in live MCF-7 cells were determined using
EGFP-α tubulin as described recently [19,21]. Briefly,
MCF-7 cells stably-expressing EGFP-α tubulin were incu-
bated with vehicle or different concentrations of GF (5
and 15 μM) for 24 h. Individual microtubules on theRathinasamy et al. BMC Cancer 2010, 10:213
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peripheral region of the MCF-7 cells were observed using
a 60 × water immersion objective in a FV 500 laser scan-
ning confocal microscope (Olympus, Tokyo, Japan)
[19,21]. The images were digitally magnified by 6 times
and were acquired at 2 or 4 s intervals for a total period of
120-180 s using the FluoView software (Olympus, Tokyo,
Japan). The lengths of the microtubules at different time
points were calculated using Image-Pro Plus software
(Media Cybernetics, Silver Spring, MD). The dynamic
instability parameters were calculated as described earlier
[2,19]. Transfection of MCF-7 cells with p53-GFP plas-
mid was done using lipofectamine-2000. Stably express-
ing p53-GFP MCF-7 cells were treated with different
concentrations of GF (15-90 μM) and the localization of
p53-GFP was studied using Nikon Eclipse TE-2000U flu-
orescent microscope. The images were analyzed with
Image-Pro Plus software.
Annexin V/propidium iodide staining
MCF-7 cells were grown in the absence and presence of
different concentrations of GF (15, 30, and 60 μM) for 48
h. Control and treated cells were stained using the
Annexin V/propidium iodide apoptosis kit, as described
earlier [19] and the cells were examined under a fluores-
cence microscope.
Effect of GF on BODIPY FL-vinblastine binding to tubulin
Goat brain tubulin (2 μM) was incubated without and
with 100 μM GF, and with 50 μM vinblastine at 37°C for
45 min. Then, 2 μM fluorescent-tagged vinblastine
(BODIPY FL-vinblastine) was added to each of the reac-
tion mixtures and incubated for an additional 20 min in
dark at 25°C. Fluorescence spectra of BODIPY FL-vin-
blastine were monitored by exciting at 490 nm.
Effect of paclitaxel on GF binding to tubulin
Tubulin (10 μM) was polymerized in presence of 1 mM
GTP, 5 mM MgCl2, and 10% DMSO without and with 15
μM paclitaxel at 37°C for 10 min. GF (50 and 100 μM) was
added to the polymerization mixtures and then tubulin
was allowed to polymerize for an additional 20 min. The
p o l y m e r s  w e r e  p e l l e t e d  d o w n  a n d  w a s h e d  w i t h  w a r m
pipes buffer. The polymers were depolymerized on ice for
1 h using 0.01% NaOH in 25 mM pipes buffer. Fluores-
cence of GF was monitored at 437 nm by excitation at 330
nm. The concentration of GF in the pellet was then calcu-
lated using the fluorescence values of known concentra-
tions. The concentration of protein in the pellet was
measured using Bradford method [22].
Docking of GF to tubulin
GF structure was obtained from the drugbank [23]. Pro-
tein coordinates were obtained from the protein data
bank [24]. Modeler9v4 [25] was used for 3D structure
modeling. The LigandFit [26] module of Discovery Studio
2.1 (Accelrys Inc., California) and Autodock4 [27] were
used for docking. Naccess V2.1.1 was used for calculating
solvent accessible surface area [28]. PyMol was used for
rendering 3D structures [29].
The crystal structure of tubulin complexed with epothi-
lone A [30] (pdb id 1TVK) was used for docking since this
has the highest resolution (2.89 Å) among all the tubulin
structures available to date. However, in this structure,
residues 35A-60A (the suffix denotes the subunit) are dis-
ordered. This region was modeled using the correspond-
ing region of β tubulin as the template. The (Φ,Ψ) values
of all the residues in the modeled region are within the
allowed region of the Ramachandran map [31]. In addi-
tion, the WHAT IF server [32] was used to check the
modeled structure (Additional file 1, Table S1). Docking
was performed for epothilone A as a control, using both
the softwares. The root mean square deviation (RMSD)
between the "predicted" and experimentally determined
binding modes of epothilone A is 2 Å.
Docking using Autodock4
Blind docking was performed by treating only GF as flex-
ible. The entire protein was enclosed in a box with a grid
spacing of 0.375 Å. Fifty docking jobs, each of hundred
runs, were carried out using the Lamarckian genetic algo-
rithm. Default values were used for all the parameters;
g_eval was set to 2,500,000 (M). The resulting 5000 bind-
ing modes were clustered using an all-atom RMSD cutoff
of 2 Å. Binding modes are ranked on the basis of cluster
size. Highly populated (viz., size ≥ 50) clusters were cho-
sen for further analysis. In these clusters, decrease in sol-
vent accessible surface area of the protein on GF binding
was calculated.
Docking using LigandFit
Binding sites were defined on tubulin surface and GF was
docked in each of these cavities. The ligand poses at these
sites were selected on the basis of shape matching, using a
cutoff distance of 3 Å between the ligand and the binding
site residues. Binding modes are ranked on the basis of
consensus scoring.
Determination of combination Index (CI)
MCF-7 cells were treated with GF (10 and 15 μM), vin-
blastine (0.5 and 1 nM) or GF along with vinblastine for
48 h. The CI was calculated by Chou and Talalay method
[33-35] using the equation:
Where, (D)1 and (D)2 are the concentrations of drug 1
(GF) and drug 2 (vinblastine) in combination that pro-
duces a given effect, (Dx)1 and (Dx)2 are the concentra-
CI D Dx D Dx = () ( ) + () ( ) 1122 //(1)Rathinasamy et al. BMC Cancer 2010, 10:213
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tions of drug 1 and drug 2 that also produces the same
effect when used alone.
The concentration of the drug that produces a particu-
lar effect (Dx) and the median dose (Dm) were calculated
as described earlier [33-35]. CI <1 indicates synergism, CI
= 1 indicates additivity, and CI >1 indicates antagonism.
Results
GF inhibited the proliferation of the MCF-7 cells and caused 
mitotic arrest
GF inhibited the proliferation of MCF-7 cells with an IC50
of 17 ± 2 μM after 48 h of incubation (one cell cycle) (Fig-
ure 1A). The proliferation was inhibited by 73 and 91% in
the presence of 30 and 60 μM of GF, respectively. GF
arrested MCF-7 cells at mitosis in a concentration depen-
dent manner (Figure 1A). For example, 2, 11, and 32% of
the cells were found in different stages of mitosis in the
absence or presence of 15 and 60 μM of GF, respectively.
Flow cytometry analysis suggested that GF inhibited
cell cycle progression of MCF-7 cells in the G2/M phase.
For example, 16, 26, 36 and 46% of cells were found to be
in the G2/M phase in the absence or presence of 30, 60
and 90 μM of GF, respectively (Figure 1B). Further, GF-
treatment increased the number of phosphohistone H3
positive MCF-7 cells in a concentration dependent man-
ner (Additional file 1, Figure S1). For example, 2.9 ± 0.2%,
12.3 ± 1.3% and 28.2 ± 3.3% of the cells were found to be
phosphohistone H3 positive in the absence and the pres-
ence of 15 and 60 μM GF, respectively suggesting that GF
treatment increased the number of mitotic cells.
GF perturbs microtubule-kinetochore attachment and the 
tension across the kinetochores in MCF-7 cells
Spindle assembly check point proteins like BubR1 and
Mad2 are known to sense the tension across the kineto-
chores and microtubule attachment to the kinetochores
[36,37]. The position of the kinetochores has been shown
by Hec1 protein (Figure 1C). In the presence of GF, Mad2
was found to localize at the kinetochores (Figure 1C).
BubR1 was also found to be localized to the kinetochores
i n  G F  t r e a t e d  c e l l s  ( A d d i t i o n a l  f i l e  1 ,  F i g u r e  S 2 ) .  T h e
results indicated that GF disrupts the attachment of
microtubules to kinetochores and also disturbs the ten-
sion across the kinetochores.
GF induced apoptotic cell death in MCF 7 cells
Although control MCF-7 cells remained viable after 48 h,
GF-treated cells were found at various stages of apopto-
sis. GF (15 and 30 μM) treated cells stained positive for
Annexin V and weakly stained with propidium iodide
indicating that the cells were in early or mid apoptotic
phase. Cells treated with 60 μM GF stained positive for
both Annexin V and propidium iodide indicating them to
be in the late apoptotic phase (Figure 1D).
GF induced the nuclear localization of p53 and p21
GF treatment strongly increased the nuclear localization
of p53 in MCF-7 cells (Additional file 1, Table S2 and S3).
For example, 3, 39, 30 and 35% of the MCF-7 cells were
found to have p53 translocated into the nucleus after 48 h
incubation with vehicle, 15, 30, and 60 μM of GF, respec-
tively (Figure 2A, Additional file 1, Table S3). Consistent
with the previous studies [2,3], GF was found to induce
multipolarity in MCF-7 cells. GF treatment also induced
the formation of fragmented nuclei/multiple nuclei in
MCF-7 cells. For example, 31 ± 7 and 50 ± 12% of the
interphase cells were with fragmented nuclei after 24 and
48 h of incubation with 90 μM GF, respectively while,
only 2 ± 1.2 and 1 ± 0.7% of vehicle-treated cells had frag-
mented nuclei (Additional file 1, Table S2 and S3).
Interestingly, the cells containing fragmented nuclei
exhibited increased accumulation of p53 in the nucleus as
compared to the mononucleated interphase cells of the
same treatment group (Figure 2A, Additional file 1, Table
S2 and S3). For example, 11 ± 1% of mononucleated cells
and 63 ± 3% of the interphase cells with fragmented
nuclei were found to have nuclear translocation of p53
after 24 h incubation with 15 μM GF. The number of
mononucleated cells containing p53 decreased with
increasing drug concentration. However, the number of
cells containing fragmented nuclei increased with
increasing drug concentration and more than 65% of
these cells containing fragmented nuclei were found to
contain enhanced concentration of p53 in their nuclei.
Similarly, MCF-7 cells transfected with GFP-p53 also
showed enhanced nuclear localization of GFP-p53 and
fragmentation of nuclei upon GF treatment (Additional
file 1, Figure S3; Additional file 1, Table S4). For example,
in the presence of 15 μM GF, 42% of the cells with frag-
mented nuclei and 12% of the mononucleated cells accu-
mulated GFP-p53 in their nuclei while only 2% of the
mononucleated control cells (vehicle-treated) had p53
localized in the nuclei. p21, the downstream target of p53,
was also observed to exhibit similar localization pattern
as p53 (Figure 2B). In the presence of 60 and 90 μM GF,
most of the cells contained multiple nuclei and enhanced
concentration of p21 in their nuclei (Figure 2B).
GF affected microtubule and chromosome organization in 
MCF-7 cells
GF (15 μM) did not alter the interphase microtubular
network as they were found to be similar to the vehicle
(0.1% DMSO) treated cells. A moderate depolymeriza-
tion of interphase microtubules was observed in the pres-
ence of 30 μM GF (data not shown). Higher
concentrations (60 and 90 μM) of GF caused depolymer-
ization of the interphase microtubules and also increased
the number of cells containing fragmented nuclei (Figure
3A). The effects of GF on the spindle microtubules wereRathinasamy et al. BMC Cancer 2010, 10:213
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more clearly noticeable than its effects on the interphase
microtubules (Figure 3B). In the presence of 15 μM GF,
few chromosomes were located near the spindle poles
and few chromosomes were lagging behind and were not
positioned at the metaphase plate. GF (≥ 30 μM) caused a
significant depolymerization of the spindle microtubules.
Spindles were found to be multipolar in the presence of
high concentrations (≥ 30 μM) of GF (Figure 3B). The
chromosomes looked like rounded mass without proper
Figure 1 GF inhibited MCF-7 cell proliferation, arrested cell cycle progression at G2/M phase, increased the accumulation of Mad2 at the 
kinetochores and induced apoptosis. (A) The effect of GF on cell proliferation (closed circle) was determined by counting the cells after 48 h of 
incubation. The mitotic index (closed triangle) was calculated by Hoechst staining method after incubating the cells without or with GF for 24 h. Each 
experiment was performed four times. Data represent mean ± SD. (B) Flow cytometric analysis showing the effects of GF on the MCF-7 cell cycle (C) 
Effect of GF on Mad2 (green) localization. Staining was also done for a kinetochore protein Hec1 (red) (D) GF induced apoptosis in MCF-7 cells. Bars 
equal to 10 μmRathinasamy et al. BMC Cancer 2010, 10:213
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alignment at the metaphase plate (Additional file 1, Fig-
ures S1 and S4).
GF treatment caused the formation of multiple poles in
MCF-7 cells as observed by γ tubulin staining. In the
presence of 15 μM GF, the distance between the two
poles was significantly decreased; however, cells contain-
ing multiple centrosomes were found to increase with
increasing concentrations of GF (Additional file 1, Figure
S4).
Western blot analysis showed that GF (15 μM) did not
significantly change the polymeric mass of tubulin. GF
decreased the polymeric tubulin mass by 14%, 18% and
30% in the cells treated with 30, 60 and 90 μM of GF,
respectively as compared to the vehicle-treated cells (Fig-
ure 3C and 3D). Similarly, the soluble tubulin mass was
found to be increased by 13%, 17% and 31% in the cells
treated with 30, 60 and 90 μM GF, respectively as com-
pared to the vehicle-treated cells (Figure 3C and 3D).
Figure 2 GF treatment increased the nuclear accumulation of p53 and p21. MCF-7 cells were incubated with different concentrations of GF (15-
90 μM) for 48 hours, fixed and processed to visualize either (A) p53 (red) and DNA (blue) or (B) p21 (red) and DNA (blue). Bar equals to 20 μm.Rathinasamy et al. BMC Cancer 2010, 10:213
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GF suppressed the dynamic instability of microtubules in 
live MCF-7 cells
Microtubules in the vehicle-treated MCF-7 cells were
highly dynamic and GF (15 μM, ~IC50) strongly sup-
pressed the dynamic instability of individual microtu-
bules in MCF-7 cells (Figure 4). GF (15 μM) reduced the
growing and shortening rates of microtubules in MCF-7
cells by 46 and 48.5% respectively (Table 1). The mean
growth length and shortening length of the microtubules
were reduced by 50 and 58%, respectively. GF (15 μM)
reduced the time microtubules spent in growing and
shortening phases by 53 and 31%, respectively while
increased the time microtubule spent in the pause state
(neither growing nor shortening detectably) by 103%
compared to the control microtubules.
The transition of a microtubule end from a shortening
phase to a growth or a pause phase is called a rescue
while the transition of a microtubule from a growing or a
pause to a shortening phase is called a catastrophe [38].
GF (15 μM) increased the length based rescue and the
catastrophe frequencies (events/μm) by 83 and 175%,
respectively compared to the control microtubules. The
time based rescue frequency (events/min) was not signif-
icantly different from the control treatment while the
time based catastrophe frequency (events/min) was
found to be decreased by 42.5% in the 15 μM GF treated
samples compared to the control cells. GF (15 μM, ~IC50)
reduced the dynamicity (dimer exchange per unit time) of
the microtubules by 72% compared to the control micro-
tubules (Table 1). In addition, 5 μM of GF also consider-
Figure 3 Effects of GF on the microtubules of MCF-7 cells. MCF-7 cells were incubated without or with different concentrations of GF for 48 h. (A) 
Microtubules (red) and chromosomes (blue) of interphase cells or (B) Microtubules (red) of metaphase cells are shown. Arrows point towards the 
poles. Bar equals to 20 and 10 μm for an interphase and a metaphase cell, respectively. (C) Effects of GF on the polymer mass of tubulin in MCF-7 cells. 
(D) Band intensities of the polymeric and soluble tubulin fractions in MCF-7 cells treated with different GF concentrations relative to the vehicle-treat-
ed cells are shown. The experiment was performed three times. Data represent mean ± SD.Rathinasamy et al. BMC Cancer 2010, 10:213
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ably suppressed the dynamic instability of individual
microtubules by reducing the rates of growing and short-
ening, and increasing the time microtubule spends in the
pause state. For example, it inhibited the dynamicity of
microtubules by 58%.
Docking analysis and in vitro competition experiments 
indicated that GF shares binding site in tubulin with 
paclitaxel
Autodock4 and LigandFit were used to identify the bind-
ing site(s) of GF (Figure 5A) in tubulin and only the bind-
ing sites that were identified by the two methods were
considered as putative binding sites. Two binding sites
were identified for GF (Figure 5B). Site A is at the intra-
dimer (αβ) interface and distinctly away from GDP,
colchicine and vinblastine binding sites (Additional file 1,
Table S5). This site is approximately equidistant from
both GTP and colchicine binding sites. Site B overlaps
with paclitaxel binding site.
GF was also docked using LigandFit with Nsave 20 to
determine the binding interactions at these two sites. The
binding poses were clustered using RMSD cutoff of 1 Å.
Both the predicted sites are primarily hydrophobic. This
can be expected from the chemical nature of GF , which
has only hydrogen bond acceptors and no hydrogen bond
donor (Figure 5A). Further, the three oxygen atoms from
the O-Me groups and the ring oxygen atom can accept
hydrogen bonds in only certain restricted directions due
to steric reasons. The residues Val74A, Glu77A, Val78A,
Thr225A, and Gly244B (suffixes A and B are subunit
identifiers) are involved in hydrophobic interaction at
Site A and the residues Asp26B, His227B, Phe270B,
Pro358B, and Leu361B are involved at Site B (Figure 5C,
D).
GF was found to be incorporated into the microtubules.
For example, 0.15 ± 0.02 and 0.24 ± 0.04 moles of GF per
tubulin dimer were found to be incorporated in microtu-
bules in the presence of 50 μM and 100 μM of GF, respec-
tively. Paclitaxel (15 μM) reduced the incorporation of GF
in microtubules to 0.1 ± 0.02 and 0.15 ± 0.02 moles of GF
per tubulin dimer. The decrease in GF incorporation in
microtubules in the presence of paclitaxel was signifi-
cantly different at 0.001 level. Since the binding affinity of
GF with tubulin is very weak with a dissociation constant
of 300 ± 12 μM [2], the incorporation ratios of GF are
expected to be low at these concentrations. The results
indicated that the binding site of GF in tubulin may over-
lap with the paclitaxel site.
The preincubation of tubulin with GF did not affect the
binding of fluorescent-tagged vinblastine to tubulin indi-
cating that GF binds at a site different from that of the
vinblastine site (Additional file 1, Figure S5). Moreover,
GF did not affect the binding of TNP-GTP (a fluorescent
analogue of GTP) to tubulin and also quenched the
intrinsic tryptophan fluorescence of GTP-bound tubulin
(data not shown). The results support the finding of the
docking analysis that GF binds to tubulin at a site, which
is distinct from the GTP binding site.
GF in combination with vinblastine synergistically 
inhibited the proliferation of MCF-7 cells
GF and vinblastine inhibited the proliferation of MCF-7
cells with a median dose of 17 μM and 1 nM, respectively
(Figure 6A and 6B). The combination of 10 μM GF with
0.5 and 1 nM vinblastine inhibited the proliferation of
Figure 4 Life history traces of individual microtubules in the ab-
sence or presence of 5 and 15 μM of GF are shown.Rathinasamy et al. BMC Cancer 2010, 10:213
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MCF-7 cells by 84 and 92%, respectively. Using combina-
torial analysis [33], CI values for the combination of 10
μM GF with 0.5 or 1 nM vinblastine were estimated to be
0.34 ± 0.1 and 0.27 ± 0.1, respectively while the combina-
tion of 15 μM GF with 0.5 and 1 nM vinblastine yielded
CI values of 0.26 ± 0.1 and 0.1 ± 0.01, respectively (Figure
6C). The results suggested that GF and vinblastine
exerted synergistic effects on MCF-7 cell proliferation.
Cells treated with either GF 10 μM or vinblastine 0.5
nM exhibited nearly normal bipolar mitotic spindles
(Additional file 1, Figure S6). When used alone, neither
GF (15 μM) nor vinblastine (1 nM) disrupted the organi-
zation of the mitotic spindle microtubules in most of the
cells; however, a small population of cells had disorga-
nized spindles. The combined treatment of GF and vin-
blastine strongly disrupted the organization of the
spindle microtubules (Additional file 1, Figure S6).
MCF-7 cells treated with GF (10 and 15 μM), or vin-
blastine (0.5 and 1 nM) exhibited nearly normal inter-
phase microtubule network as observed in the control
cells. The combination of 10 μM GF with either 0.5 or 1
nM vinblastine caused significant depolymerization of
the interphase microtubules. The combination of 15 μM
GF with either 0.5 or 1 nM vinblastine strongly depo-
lymerized interphase microtubules (Additional file 1, Fig-
ure S7). The finding that the combination of GF and
vinblastine induced stronger depolymerizing effects on
the spindles and interphase microtubules than either of
the drugs used alone provided a mechanistic basis for
their synergistic activity on cell proliferation.
Discussion
GF (≤ IC50) strongly suppressed the dynamics of individ-
ual microtubules in live MCF-7 cells without detectably
altering the microtubule network. However, at higher
concentrations, GF induced significant depolymerization
of both the mitotic spindles and the interphase microtu-
bules. The suppressive effects of GF on the dynamic
instability of interphase microtubules of MCF-7 cells
were found to be qualitatively similar to its effects on the
bovine brain microtubules in vitro [2]. In our studies, the
IC50 of GF for the inhibition of cell proliferation has been
found to be 17 ± 2 μM, which is comparable to some of
the anticancer agents that are undergoing clinical trials.
For example, estramustine (clinical trials.gov identifier
NCT00151086), curcumin (NCT00094445) and noscap-
ine (NCT00912899) inhibit the proliferation of MCF-7
cells with the IC50 of 5 ± 1 μM [21], 12 ± 0.6 μM [39] and
39.6 ± 2.2 μM [40], respectively.
Table 1: Effects of GF on the dynamic instability parameters of individual MTs
GF (μM)
051 5
Rate (μm/min)
Growing 18.5 ± 4 12.0 ± 2.2 a 10.0 ± 2.0a
Shortening 19.6 ± 5 12.7 ± 4.6 a 10.1 ± 2.6a
Length Change (μm)
Growth length 2.0 ± 0.8 1.4 ± 0.6b 1.0 ± 0.4a
Shortening length 2.4 ± 0.7 1.4 ± 1c 1.0 ± 0.3a
% Time in phase
Growing 44.0 ± 10 33.0 ± 10a 20.5 ± 6a
Shortening 25.5 ± 10 14.5 ± 5a 17.5 ± 4b
Pause 30.5 ± 9 52.5 ± 9a 62.0 ± 9a
Frequency (events/min)
Catastrophe 4.0 ± 2 1.6 ± 0.5a 2.3 ± 0.8b
Rescue 10.0 ± 3 10.0 ± 4d 10.0 ± 2.6c
Frequency (events/μm)
Catastrophe 0.40 ± 0.2 0.5 ± 0.3d 1.1 ± 0.5a
Rescue 0.6 ± 0.3 0.9 ± 0.5b 1.1 ± 0.3a
Dynamicity (μm/min) 13.7 ± 4 5.7 ± 2a 3.8 ± 1.2a
Data are average ± SD, n = 22 MTs in control and n = 21 MTs in 5 & 15 mM GF treated cells; a, P < 0.001; b, P < 0.01; c, P < 0.05; d, statistically 
not significantRathinasamy et al. BMC Cancer 2010, 10:213
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GF was also found to be incorporated into the microtu-
bules in high stoichiometry (0.24 molecules of GF per
tubulin dimer) suggesting that GF binds along the length
of the microtubules. Like paclitaxel [41,42], GF did not
strongly influence the time based catastrophe and rescue
frequencies. GF suppressed the dynamics by reducing the
rate and extent of the growing and shortening excursions
and increasing the time microtubule spent in the pause
state. The docking studies indicated that GF has two
potential binding sites in tubulin; one of these sites is
overlapping with the paclitaxel binding site and the other
lies at the interface of αβ tubulin, which is distinct from
the GDP, vinblastine, and colchicine sites. The docking
analysis is consistent with the findings that GF neither
binds to the colchicine site [12] nor the vinblastine site in
tubulin (Additional file 1, Figure S5; Additional file 1,
Table S5). A competition experiment with paclitaxel
showed that paclitaxel reduced the binding of GF to tubu-
lin in microtubules supporting the computational analy-
sis data that GF binding site partially overlaps with the
paclitaxel site in tubulin. Paclitaxel is known to stabilize
microtubule dynamics [42] and like GF, paclitaxel has
been shown to bind along the length of microtubules [41].
Therefore, it is logical to propose that GF stabilizes
microtubules dynamics by binding to tubulin in the pacli-
t a x e l  s i t e .  I t  i s  l i k e l y  t h a t  a t  h i g h e r  c o n c e n t r a t i o n s  G F
binds to tubulin in the putative second site, which is
Figure 5 Mode of interaction of GF with tubulin. (A) Structure of GF. The conformation of the O-Me groups are chosen arbitrarily. Color code: car-
bon, blue; oxygen, red; hydrogen, grey; chlorine, green. (B) Cartoon rendering of the αβ tubulin heterodimer (PDB id 1TVK) showing the location of 
the binding sites for colchicine, paclitaxel and vinblastine (purple), GTP and GDP (black) and GF (blue). The "upper" domain is α tubulin and the "lower" 
domain is β tubulin. In this view, GTP and GDP are partly hidden. Vinblastine binds at the inter-dimer (αβ)-interface and hence, is shown both at the 
top and bottom. Colchicine binds at the intra-dimer interface (αβ) and paclitaxel binds to the β-subunit. The binding sites for GF, one at the interface 
(site A) and the other overlapping with that of paclitaxel (site B), are predicted by docking; all others are based on X-ray crystallographic studies. (C) 
and (D) Representative binding modes of GF in site A (C) and site B (D) obtained by docking. Atoms are colored by element type except for carbon 
(cyan for GF and grey for binding site residues). Hydrophobic residues constituting the binding pocket and polar residues within 3 Å of GF are shown.Rathinasamy et al. BMC Cancer 2010, 10:213
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located at the intra-dimer interface and induces microtu-
bule depolymerization.
Defects in the microtubule-kinetochore attachment
and the tension across the sister kinetochores are sensed
by the check point proteins and the accumulation of
check point proteins at the kinetochore region is thought
to prevent the cells to enter into the anaphase until the
defects are corrected [20,21,36,37]. The enhanced local-
ization of BubR1 and Mad2 on the kinetochores upon GF
treatment suggested that GF inhibited the extinction of
checkpoint proteins from the kinetochores (Figure 1C;
Additional file 1, Figure S2). The accumulation of BubR1
and Mad2 at the kinetochores activated the mitotic
checkpoint and arrested the cells at mitosis. These mitot-
ically blocked cells either undergo apoptosis or make an
aberrant mitotic exit without cytokinesis resulting in cells
with fragmented nuclei, which eventually undergo apop-
tosis [3,43]. The presence of multiple poles in GF treated
cells probably results in improper chromosome segrega-
tion leading to the formation of multiple nuclei. The
FACS analysis did not show an increase in DNA content
(> 4N) indicating that multiple nuclei in the cells are
indeed due to the improper chromosome segregation and
not due to the multiplication of DNA. GF treatment
caused a strong increase in multipolar mitosis leading to
the formation of fragmented nuclei of varying sizes in
MCF-7 cells. Most (> 60%) of these cells with fragmented
nuclei had much higher accumulation of p53 as com-
pared to the mononucleated cells suggesting that the cells
that committed aberrant exit from the mitotic block with
fragmented nuclei underwent apoptosis. Therefore, GF
may induce apoptosis in MCF-7 cells via a series of con-
certed events, which includes formation of multipolar
spindles, fragmentation of the nucleus, nuclear accumu-
lation of p53, and finally p53 dependent induction of
apoptosis. Cells treated with higher GF concentrations (>
30 μM) had hyper amplified centrosomes (Figure 3B;
Additional file 1, Figure S4) and completely disorganized
multipolar mitosis (Figure 3B). As a result, GF induced a
concentration and a time dependent increase in the num-
ber of cells containing fragmented nuclei. The organiza-
tion of centrosomes plays an important role in the
successful completion of mitosis. Microtubule interacting
drugs like paclitaxel, nocodazole, vinblastine and podo-
phyllotoxin were shown to affect the organization of the
centrosomes and cause functional impairment [44]. It has
been found that GF inhibited the centrosomal clustering
without interfering with the functions of NuMA and
dynein and it was indicated that the alteration of the
interphase microtubule stability by GF might be the rea-
son for the inhibition of centrosomal clustering [3]. The
evidence presented in this study strongly suggested that
the kinetic suppression of microtubule dynamics induces
mitotic irregularities and nuclear accumulation of p53.
Drugs having adverse side effects can be successfully
used for chemotherapy if their effective doses are reduced
significantly. Moreover, the use of combination of two or
more drugs reduces the chances of survival of the resis-
Figure 6 Combination of GF and vinblastine exerted synergistic 
effects in inhibiting MCF-7 cell proliferation. The median effect 
plots for the inhibition of cell proliferation in the presence of GF (A) and 
vinblastine (B) are shown. (C) The effects of the combination of GF and 
vinblastine (Vinb) on MCF-7 cell proliferation after 48 h treatment are 
shown as combination index. Data are average of four experiments 
and error bars represent SD.Rathinasamy et al. BMC Cancer 2010, 10:213
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tant cancer cells [44]. For example, the use of haloperidol
in combination with vinblastine reversed the resistance of
K562/VBL cells to vinblastine [45]. In this work, we have
found that the combination of GF and vinblastine exhib-
ited strong synergistic effects on the inhibition of prolif-
eration of MCF-7 cells.
Conclusions
The study provided mechanistic insights into the antipro-
liferative action of GF on MCF-7 cells. GF arrested MCF-
7 cells at mitosis and perturbed microtubule dynamic
instability in cells, thus driving the cells to undergo pro-
grammed cell death. It exerts these effects by binding
along the length of the microtubules, possibly at the
paclitaxel site. Its potential activity against breast cancer
cells has been explored for the first time and also the
combination studies with vinblastine show that the two
drugs together may successfully be used in the treatment
of breast cancer.
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